Retatrutide Delivers Unprecedented Weight Loss in Phase 3

Published Date: 22 May 2026

Participants on weekly injections of 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, and 45.3% of participants achieved ≥ 30% weight loss.

Read Full News

Latest News

Migraine With Aura Tied to Higher Stroke Risk

Migraine with aura is associated with an increased risk for ischemic stroke in middle-aged and older adults, particularly men younger than 72 years, a new study shows.

Semaglutide Tablet Wins UK Approval for Weight Loss

The MHRA has approved the UK's first oral semaglutide tablet for obesity, with NHS availability pending a NICE evaluation.

Is Modern Medicine Losing the Art of Listening?

Patients place high value on listening, trust, and clear communication, which are factors that shape adherence, satisfaction, and the overall experience of care.

How ‘Ozempic Mouth’ Became a Thing — and How to Treat It

GLP-1 medications may not directly cause oral health problems, but their mechanisms can. Take a cue from dental experts for insights on how to manage these oral effects.

ANTHEM-HFrEF: What Can We Learn From an Unfinished Trial?

Despite early termination, the ANTHEM-HFrEF trial holds important lessons for investigators.

Extrahepatic Cancer Risk Varies by Liver Disease Subgroups

The risk for extrahepatic cancers varies among subgroups of steatotic liver disease, with the highest risk seen in patients with metabolic dysfunction and alcohol-associated liver disease.

Todays Updates

HIV Care Coordination Program May Reduce Deaths in NYC

New York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Off-Label Rxs: Thinking Out of the Box for Skin Diseases

Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.

Todays Updates

HIV Care Coordination Program May Reduce Deaths in NYC

New York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Off-Label Rxs: Thinking Out of the Box for Skin Diseases

Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.

Latest News

Migraine with aura is associated with an increased risk for ischemic stroke in middle-aged and older adults, particularly men younger than 72 years, a new study shows.

The MHRA has approved the UK's first oral semaglutide tablet for obesity, with NHS availability pending a NICE evaluation.

Patients place high value on listening, trust, and clear communication, which are factors that shape adherence, satisfaction, and the overall experience of care.

GLP-1 medications may not directly cause oral health problems, but their mechanisms can. Take a cue from dental experts for insights on how to manage these oral effects.

Despite early termination, the ANTHEM-HFrEF trial holds important lessons for investigators.

The risk for extrahepatic cancers varies among subgroups of steatotic liver disease, with the highest risk seen in patients with metabolic dysfunction and alcohol-associated liver disease.

News All Time

Heat-Related CVD Burden May Nearly Triple by 2050

Rising temperatures are projected to nearly triple the burden of cardiovascular disease in the US by 2050 under a scenario of high emissions of greenhouse gases, a study estimates.

Stroke Treatment Outcomes Vary by Cancer Subtype

Patients with cancer who suffer an acute ischaemic stroke face higher odds of in-hospital death and bleeding after recanalisation therapy, with outcomes varying by cancer subtypes.

Lung Ultrasound Plus CRP May Guide Antibiotic Decisions

Lung ultrasound may help identify a bacterial component in children with acute lower respiratory tract infections and may guide antibiotic decisions when paired with C-reactive protein.

Serum Potassium Concentrations Shape Heart Failure Risk

A meta-analysis identifies the optimal serum potassium range linked to a lower risk for death and hospitalisation in heart failure, with low potassium tied to worse outcomes in HFrEF.

Semaglutide Accepted in Scotland for CV Risk Reduction

The SMC accepted semaglutide for adults with established cardiovascular disease and overweight or obesity, expanding its role beyond weight management.

ACC/AHA Release First-Ever Guideline for CKM Syndrome

New multisociety guidelines shift from obesity alone to a combined construct of cardiovascular-kidney-metabolic health that emphasizes cohesive care management.

Could the Iran Conflict Disrupt MRI Services?

Strikes on Qatar's gas facilities have cut global helium supply, raising concerns for hospitals running older MRI scanners.

Common Metabolic Issue in Women Tied to Mortality Risk

Women with polyendocrine metabolic ovarian syndrome face a higher risk for all-cause mortality than those without the condition, a Finnish study shows.

Rivaroxaban Flops for Prevention in Advanced CKD

Low-dose rivaroxaban failed to cut the high cardiovascular risk in this population in a large randomized trial, contrasting prevention seen in other high-risk populations.

Advance Directives May Reduce Unnecessary End-of-Life Care

Older adults close to death often receive unnecessary end-of-life medical treatments in hospitals.

Obesity Stigma: Is Art History the Fix?

Learning through art history that obesity once denoted prosperity, strength, and beauty, may help healthcare providers treat patients with more compassion, a researcher proposes.

Retatrutide Data Show Dramatic Weight Loss, Other Benefits

Full results from two Lilly trials of the novel triple hormone receptor agonist show reductions in A1c, osteoarthritis knee pain, and obstructive sleep apnea.

Digoxin Shows Signs of a Heart Failure Revival

New trial data from the Heart Failure 2026 conference suggest that low-dose digoxin may reduce worsening HF events, reigniting debate over digitalis therapy.

Solutions Emerging for Post-GLP-1 Weight Regain

As real-world studies show high rates of GLP-1 discontinuation and rapid weight regain, new interventions may help patients maintain weight loss.

FDA Neurology Roundup: May 2026

A monthly snapshot of FDA activity involving therapies for the prevention and treatment of neurologic diseases.

Is At-Home, Extended-Release Ketamine Coming to Market Soon?

A new take-home tablet is in development, but will the features that make it attractive blunt the experience that could be part of ketamine’s therapeutic value?

Recommended News For You

World's premier cancer institute faces crippling cuts and chaos

Patient Endured 9 Years of Chemotherapy for Cancer He Never Had

New imaging guidelines for head and neck cancers, a step toward practice change

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.

AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns

Data indicate 1 in 3 US adults unaware of connection between HPV and cancers

NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.

Recommended Articles For You

Vaccines that can help prevent cancer 

Innovative Advances in Oncology for Specialists 

Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches 

Unlocking the Secrets of Improved Ovarian Cancer Survival Rates 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

2.

Is global cancer care losing its human touch?

3.

New study links air pollution with higher rates of head and neck cancer

4.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

5.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

1.

Contemporary Trends in Oncology and Patient Outcomes

2.

Survival Rates in Cancer: Focus on Acute Myeloid Leukemia and Other Malignancies

3.

Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025

4.

Emerging Frameworks in Oncology in Clinical Decision-Making

5.

The Basics of M.C.V Normal Range for Better Health Management

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

2.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

3.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

4.

The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion

5.

Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot